[Clinical evaluation of carbenicillin in a daily dose of 10 g in chronic airway infections].
Carbenicillin (CBPC) was evaluated in 4 patients with chronic airway infections and 2 with infections secondary to lung cancer. The daily dose of CBPC was 10 g for all patients. The following results were obtained. Three out of 4 patients with chronic airway infections showed good response. Both cases with infection secondary to lung cancer showed good response. The overall effectiveness rate was 83.3%. There were no side effects or abnormal laboratory values related to carbenicillin therapy. CBPC is still considered to be a drug of choice for the initial acute exacerbation of chronic airway infection and for infections secondary to lung cancer.
D000328:Adult; D000368:Aged; D002228:Carbenicillin / Q000008:administration & dosage*; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008175:Lung Neoplasms / Q000150:complications; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000209:etiology
D002228:Carbenicillin